The Effect of Metformin on Survival Outcomes of Non-Metastatic Breast Cancer Patients with Type 2 Diabetes

Behrouzi, Bita; Zokaasadi, Mohammad; Mohagheghi, Mohammad Ali; Emami, Amir; Sadighi, Sanambar

doi:10.31557/apjcp.2021.22.2.611

Cited by 4 publications

(10 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The meta‐analyses included 101 publications reporting postdiagnosis BMI (assessed from at‐diagnosis to on average 5.8 years postdiagnosis), waist circumference (at‐diagnosis to 7.9 years postdiagnosis), waist‐to‐hip ratio (at‐diagnosis to 2.5 years postdiagnosis) and pre‐ to postdiagnosis weight gain or loss (from 1 year before to 1 year or more after diagnosis). 27 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 , 81 , 82 , 83 , 84 , 85 , 86 , 87 , 88 , 89 , …”

Section: Resultsmentioning

confidence: 99%

“… 27 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 , 81 , 82 , 83 , 84 , 85 , 86 , 87 , 88 , 89 , 90 , 91 , 92 , 93 , 94 , ...…”

Section: Resultsunclassified

“…The respective linear dose‐response meta‐analyses included 64 studies that reported all‐cause mortality (52 publications, 32 507 deaths), 39 , 40 , 41 , 43 , 44 , 45 , 46 , 53 , 54 , 55 , 57 , 63 , 64 , 65 , 66 , 67 , 68 , 70 , 72 , 78 , 79 , 81 , 82 , 84 , 85 , 88 , 89 , 91 , 93 , 94 , 95 , 97 , 98 , 100 , 102 , 104 , 105 , 109 , 111 , 112 , 113 , 114 , 116 , 118 , 120 , 123 , 125 , 126 , 127 , 129 , 130 , 135 39 studies that reported breast c...…”

Section: Resultsmentioning

confidence: 99%

“…However, few studies were included in some subgroups leading to wide 95% CIs and limiting the ability to assess/explain heterogeneity. Meta‐regression analyses indicated that tumor invasiveness or stage may partly explain the heterogeneity observed for breast cancer recurrence ( I 2 = 54%), with the studies of invasive and in situ breast cancers showing a higher average positive association (five studies/publications) 55 , 96 , 110 , 112 , 127 compared with studies with only invasive cancers (50 studies, 41 publications), 40 , 41 , 43 , 44 , 45 , 46 , 48 , 51 , 54 , 56 , 59 , 63 , 64 , 65 , 66 , 68 , 69 , 70 , 72 , 74 , 79 , 84 , 85 , 88 , 89 , 92 , 94 , 102 , 104 , 106 , 115 , 116 , 120 , 121 , 122 , 123 , 124 , 125 , 130 , 131 , 136 and the studies of metastatic breast cancers showing inverse associations (eight studies, two publicatio...…”

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

Postdiagnosis body fatness, weight change and breast cancer prognosis: Global Cancer Update Program (CUP global) systematic literature review and meta‐analysis

Chan

Vieira

Abar

et al. 2022

Intl Journal of Cancer

View full text Add to dashboard Cite

Previous evidence on postdiagnosis body fatness and mortality after breast cancer was graded as limited-suggestive. To evaluate the evidence on body mass index (BMI), waist circumference, waist-hip-ratio and weight change in relation to breast cancer prognosis, an updated systematic review was conducted. PubMed and Embase were searched for relevant studies published up to 31 October, 2021. Random-effects meta-analyses were conducted to estimate summary relative risks (RRs).The evidence was judged by an independent Expert Panel using pre-defined grading criteria. One randomized controlled trial and 225 observational studies were reviewed (220 publications). There was strong evidence (likelihood of causality: probable) that higher postdiagnosis BMI was associated with increased all-cause mortality (64 studies, 32 507 deaths), breast cancer-specific mortality (39 studies, 14 106 deaths) and second primary breast cancer (11 studies, 5248 events). The respective summary RRs and 95% confidence intervals per 5 kg/m 2 BMI were 1.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsunclassified

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Postdiagnosis body fatness, weight change and breast cancer prognosis: Global Cancer Update Program (CUP global) systematic literature review and meta‐analysis

Chan

Vieira

Abar

et al. 2022

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…A series of studies have assessed whether the use of insulinsensitizing medications, such as metformin [95][96][97][98][119][120][121][122][123][124] and thiazolidinediones (TZDs) [119,120,125,126], may lower the incidence of cancer in diabetic patients (Fig. 3).…”

Section: The Potential Effect Of Diabetes Medication Metformin In Cancer Preventionmentioning

confidence: 99%

Obesity, Diabetes, and Increased Cancer Progression

2021

View full text Add to dashboard Cite

Rates of obesity and diabetes have increased significantly over the past decades and the prevalence is expected to continue to rise further in the coming years. Many observations suggest that obesity and diabetes are associated with an increased risk of developing several types of cancers, including liver, pancreatic, endometrial, colorectal, and post-menopausal breast cancer. The path towards developing obesity and diabetes is affected by multiple factors, including adipokines, inflammatory cytokines, growth hormones, insulin resistance, and hyperlipidemia. The metabolic abnormalities associated with changes in the levels of these factors in obesity and diabetes have the potential to significantly contribute to the development and progression of cancer through the regulation of distinct signaling pathways. Here, we highlight the cellular and molecular pathways that constitute the links between obesity, diabetes, cancer risk and mortality. This includes a description of the existing evidence supporting the obesity-driven morphological and functional alternations of cancer cells and adipocytes through complex interactions within the tumor microenvironment.

show abstract

Efficacy of metformin combined with liraglutide on the glucose and lipid metabolism, vascular endothelial function, and oxidative stress of patients with T2DM and metabolic syndrome

Liu

2023

Pak J Med Sci

View full text Add to dashboard Cite

Objective: This study evaluates the impact of metformin combined with liraglutide on the glucose and lipid metabolism, oxidative stress, and vascular endothelium of patients with type-2 diabetes mellitus (T2DM) and metabolic syndrome. Methods: Medical records of 78 patients with T2DM and metabolic syndrome, admitted to Caoxian People’s Hospital from July 2021 to July 2022, were retrospectively analysed. Thirty five patients were treated with metformin (control group), and 43 patients were treated with metformin combined with liraglutide (observation group). Indexes of glucose and lipid metabolism, function of vascular endothelium and the oxidative stress of both groups were compared before and after the treatment. Results: There was a significant decrease in the levels of fasting plasma glucose (FPG), Glycosylated Hemoglobin A1c (HbA1c), triglyceride (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), systolic blood pressure (SBP), diastolic blood pressure (DBP) and waist circumference in both groups three months after the treatment, These indexes were significantly lower in the observation group compared to the control group (P<0.05). High-density lipoprotein cholesterol (HDL-C) levels were higher in the observation group (P<0.05). There was a significant improvement in the levels of nitric oxide (NO), endothelin-1 (ET-1), superoxide dismutase (SOD), and malondialdehyde (MDA) after the treatment, and these indexes were markedly better in the observation group compared to the control group (P<0.05). Conclusions: Metformin combined with liraglutide treatment is associated with better outcomes than metformin alone in patients with T2DM and metabolic syndrome. Combined treatment results in improved glucose and lipid metabolism, vascular endothelial function, and oxidative stress index values. doi: https://doi.org/10.12669/pjms.40.1.7936 How to cite this: Liu Z. Efficacy of metformin combined with liraglutide on the glucose and lipid metabolism, vascular endothelial function, and oxidative stress of patients with T2DM and metabolic syndrome. Pak J Med Sci. 2023;39(6):26-30. doi: https://doi.org/10.12669/pjms.40.1.7936 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

show abstract

The Effect of Metformin on Survival Outcomes of Non-Metastatic Breast Cancer Patients with Type 2 Diabetes

Cited by 4 publications

References 34 publications

Postdiagnosis body fatness, weight change and breast cancer prognosis: Global Cancer Update Program (CUP global) systematic literature review and meta‐analysis

Postdiagnosis body fatness, weight change and breast cancer prognosis: Global Cancer Update Program (CUP global) systematic literature review and meta‐analysis

Obesity, Diabetes, and Increased Cancer Progression

Efficacy of metformin combined with liraglutide on the glucose and lipid metabolism, vascular endothelial function, and oxidative stress of patients with T2DM and metabolic syndrome

Contact Info

Product

Resources

About